253 related articles for article (PubMed ID: 35072573)
1. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.
Wang R; Fan H; Sun M; Lv Z; Yi W
Technol Cancer Res Treat; 2022; 21():15330338211070689. PubMed ID: 35072573
[TBL] [Abstract][Full Text] [Related]
2. LncAY controls BMI1 expression and activates BMI1/Wnt/β-catenin signaling axis in hepatocellular carcinoma.
Chen MH; Fu LS; Zhang F; Yang Y; Wu XZ
Life Sci; 2021 Sep; 280():119748. PubMed ID: 34174322
[TBL] [Abstract][Full Text] [Related]
3. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
5. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
6. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.
Xu CR; Lee S; Ho C; Bommi P; Huang SA; Cheung ST; Dimri GP; Chen X
Mol Cancer Res; 2009 Dec; 7(12):1937-45. PubMed ID: 19934271
[TBL] [Abstract][Full Text] [Related]
8. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract][Full Text] [Related]
9. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.
Qi S; Li B; Yang T; Liu Y; Cao S; He X; Zhang P; Li L; Xu C
Int J Mol Sci; 2014 Nov; 15(11):20004-21. PubMed ID: 25372945
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 is required for hepatic progenitor cell expansion and liver tumor development.
Fan L; Xu C; Wang C; Tao J; Ho C; Jiang L; Gui B; Huang S; Evert M; Calvisi DF; Chen X
PLoS One; 2012; 7(9):e46472. PubMed ID: 23029524
[TBL] [Abstract][Full Text] [Related]
11. Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.
Zhang R; Real CI; Liu C; Baba HA; Gerken G; Lu M; Broering R
Int J Cancer; 2017 Jul; 141(2):354-363. PubMed ID: 28419472
[TBL] [Abstract][Full Text] [Related]
12. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
Chiba T; Miyagi S; Saraya A; Aoki R; Seki A; Morita Y; Yonemitsu Y; Yokosuka O; Taniguchi H; Nakauchi H; Iwama A
Cancer Res; 2008 Oct; 68(19):7742-9. PubMed ID: 18829528
[TBL] [Abstract][Full Text] [Related]
13. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
Zhang R; Xu LB; Yue XJ; Yu XH; Wang J; Liu C
Oncol Rep; 2013 Mar; 29(3):967-74. PubMed ID: 23242307
[TBL] [Abstract][Full Text] [Related]
14. BMI1 in the heart: Novel functions beyond tumorigenesis.
Yang D; Liu HQ; Yang Z; Fan D; Tang QZ
EBioMedicine; 2021 Jan; 63():103193. PubMed ID: 33421944
[TBL] [Abstract][Full Text] [Related]
15. BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.
Yang W; Wu Z; Yang K; Han Y; Chen Y; Zhao W; Huang F; Jin Y; Jin W
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H61-H69. PubMed ID: 30359076
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.
Bartucci M; Hussein MS; Huselid E; Flaherty K; Patrizii M; Laddha SV; Kui C; Bigos RA; Gilleran JA; El Ansary MMS; Awad MAM; Kimball SD; Augeri DJ; Sabaawy HE
Target Oncol; 2017 Aug; 12(4):449-462. PubMed ID: 28589491
[TBL] [Abstract][Full Text] [Related]
17. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.
Chiba T; Seki A; Aoki R; Ichikawa H; Negishi M; Miyagi S; Oguro H; Saraya A; Kamiya A; Nakauchi H; Yokosuka O; Iwama A
Hepatology; 2010 Sep; 52(3):1111-23. PubMed ID: 20648475
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
19. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.
Chen SJ; Chen YT; Zeng LJ; Zhang QB; Lian GD; Li JJ; Yang KG; Huang CM; Li YQ; Chu ZH; Huang KH
Tumour Biol; 2016 Aug; 37(8):11299-309. PubMed ID: 26951514
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 drives hepatocarcinogenesis by repressing the TGFβ2/SMAD signalling axis.
Li B; Chen Y; Wang F; Guo J; Fu W; Li M; Zheng Q; Liu Y; Fan L; Li L; Xu C
Oncogene; 2020 Jan; 39(5):1063-1079. PubMed ID: 31591477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
